For too long AD have been a too highly variable environment for clinical research!

-The patients present with highly variable conditions

-The treatments have widely different modes of action and possible targets

-The assessment measures are highly variable and subject to large errors

No wonder it has been almost impossible to pick up any indicators or signals of benefit!!!

At last – here is at the start a 8 point classification system for patients based on amyloid, tau and neurodegeneration AT(N)


It means a formal biomarker-based disease continuum replacing the   2011 idea of three stages—preclinical, mild cognitive impairment, and dementia